Streetbeat News

TENKU

TenX Keane Acquisition Corp.

https://www.tenxkeane.com

Industry

Shell Companies

TenX Keane Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. The company was founded in 2021 and is based in New York, New York.

Open

45.84

Mkt cap

273M

Volume

1.7K

High

45.84

P/E Ratio

N/A

52-wk high

45.84

Low

40.01

Div yield

N/A

52-wk low

10.77

Citius Pharmaceuticals has agreed to merge its wholly owned subsidiary with TenX Keane Acquisition to form Citius Oncology, Inc. Upon closing, Citius Pharma will receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 11:35 am

TenX Keane Acquisition (NASDAQ:TENKU) has extended the deadline for its initial business combination from October 18, 2023, to January 18, 2024. To facilitate this, the company has deposited $660,000 into its trust account, representing $0.10 per public share. The payment was made by 10XYZ Holdings LP, the company's sponsor.

Portfolio Pulse from Happy Mohamed

October 18, 2023 | 8:03 pm

TenX Keane Acquisition (NASDAQ:TENKU) has extended the deadline for its initial business combination from July 18, 2023 to October 18, 2023. The company has deposited $660,000 into its trust account to facilitate this extension. The payment was made by 10XYZ Holdings LP, the sponsor of the company.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 8:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.